Even After a 61% Price Cut, a New Breast Cancer Drug Fails China’s Cost-Effectiveness Test
A pharmacoeconomic analysis using Asian cohort data from the INAVO120 trial finds that inavolisib plus palbociclib/fulvestrant is not cost-effective nationally ...
